GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Gross Profit

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Gross Profit : $49.15 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Gross Profit?

Clinuvel Pharmaceuticals's gross profit for the six months ended in Dec. 2023 was $20.87 Mil. Clinuvel Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $49.15 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Clinuvel Pharmaceuticals's gross profit for the six months ended in Dec. 2023 was $20.87 Mil. Clinuvel Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $21.59 Mil. Therefore, Clinuvel Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 96.67%.

Clinuvel Pharmaceuticals had a gross margin of 96.67% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Clinuvel Pharmaceuticals was 90.27%. The lowest was -48.09%. And the median was 76.14%.


Clinuvel Pharmaceuticals Gross Profit Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Gross Profit Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.79 15.83 33.07 38.82 46.67

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.70 24.37 18.49 28.28 20.87

Competitive Comparison of Clinuvel Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Gross Profit falls into.



Clinuvel Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Clinuvel Pharmaceuticals's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=52.564 - 5.898
=46.67

Clinuvel Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=21.591 - 0.718
=20.87

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $49.15 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Clinuvel Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=20.87 / 21.591
=96.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Clinuvel Pharmaceuticals had a gross margin of 96.67% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Clinuvel Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-30-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-19-2022

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022

CLINUVEL Trial Results Show Drug Reduces DNA Damage

By Stock market mentor Stock market mentor 01-16-2023

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL Expands Pharmaceutical Portfolio

By Don Li2 Don Li2 11-08-2021